George Yendewa is an Infectious Disease physician affiliated with University Hospitals of Cleveland. OpenAlex indexes 104 publications with 1,154 citations (h-index 19); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11100 Euclid Ave
Cleveland, OH 441061716
Telephone
216-844-8500Provider last certified this registry record 13 Jan 2021.
Clinical trials
- AIDS 347: IL-6 Blockade in Treated HIV Infection
Sponsor: Case Western Reserve University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
12 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year20257 payments
- La Jolla Pharmaceutical CompanyProgram year20252 payments
- Shionogi IncProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
72.5%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor20.7%Tivicay72%Juluca20%Isentress9%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor14.1%Descovy67%Triumeq33%Part D<11 patients+ 9 more classes in this area
Cardiovascular
12%ACE inhibitor3.6%Lisinopril100%Part D<11 patientsStatin2.8%Atorvastatin Calcium100%Part D<11 patients+ 3 more classes in this area
Nervous system
3.7%Aminoketone1.9%Bupropion Hcl Sr100%Part D<11 patientsGabapentinoids1.8%Lyrica100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2026 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Michael Lederman, MD
University Hospitals of Cleveland
Anthony Furlan
University Hospitals of Cleveland
Joseph Sabik, MD
University Hospitals of Cleveland
Hans Luders
University Hospitals of Cleveland
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”